Stivarga 40 mg film-coated tablets clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Evaluation of treatment PERSOnalization based on its therapeutic monitoring in patients with metastatic colorectal cancer treated with regorafenib
This study looks at how different levels of a cancer medicine called Stivarga (regorafenib) in the blood affect how well it works for people with advanced bowel cancer. Researchers want to find the best amount of medicine for each patient to improve their treatment.
For: metastatic colorectal cancerFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixeddose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer
This study is testing a new combination medicine (relatlimab-nivolumab) for advanced bowel cancer that has spread. It compares it to existing treatments (Lonsurf or Stivarga) to see if it helps people live longer and improves their quality of life.
For: Metastatic Colorectal CancerBelgium · Spain · France - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
This study is testing a new medicine, BMS-986288, alone and with another drug, nivolumab. It's for people with various advanced cancers. The main goals are to check for side effects and how well the new medicine works against the cancer.
For: Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN) · non-small cell lung cancer (NSCLC) · cutaneous melanomaSpain · France · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Randomized, Openlabel, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation
This study looks at new treatments for bowel cancer that has spread and has a specific gene change (KRAS p.G12C mutation). It compares a new drug combination (sotorasib and panitumumab) with standard treatments to see which works best and is safest.
For: Colorectal Cancer (CRC)Italy · Germany · Greece